Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Microtubule associated proteins 1B (MAP1B) are important components of neurocytoskeletal proteins and are widely expressed in the central and peripheral nervous systems. They are distributed in neuronal cell bodies, axons, dendrites and synapses. The dynamic state of the tube and the promotion of microtubule polymerization into bundles play an important role in axon guidance, elongation and sudden triggering. MAP1B is a high-molecular-weight microtubule-associated protein (MAPs) expressed early in the development of the nervous system. It is abundantly expressed in the growing neurites and is required for axon growth.
Phosphorylation Regulation of MAP1B
MAP1B and its phosphorylated subtype (PMAP1B) are widely distributed in the central nervous system (CNS) and the peripheral nervous system (PNS). MAP1B is mainly distributed in neuronal cell bodies and dendrites, while P-MAP1B is mainly present in growing axons and concentrated at the ends of axons close to the growth cone. MAP1B and P-MAP1B are highly expressed in the early developmental stage of the nervous system. With the developmental maturation, the expression of MAP1B and P-MAP1B is gradually decreased in most areas of CNS. However, in adult PNS, the expression of MAP1B and P-MAP1B remains relatively high. The study also found that P-MAP1B has two forms, I and II, which are denoted as P I-MAP1B and P II-MAP1B, respectively.They are related to the formation and remodeling of mature neural systems.
The phosphorylation of MAP1B is positively regulated by JNK 1 (c-Jun NH2 -terminal protein kinase). When the gene encoding JNK 1 is knocked out, the phosphorylation of MAP1B occurs, and dendrites and axonal microtubules are progressively deleted. This indicates that JNK 1 is a key regulator of microtubule-associated protein activity and microtubule assembly. P35 promotes the in vitro regulation of the biological function of MAP1B by cyclin-dependent protein kinase (CDK5).

Figure 1. Model of regulation of EBs localization by MAP1B during neurite/axon outgrowth. (Tortosa, et al. 2013)
The Role of MAP1B in Neurodevelopment
MAP1B induces neurotubule bundle reorganization, which regulates the dynamic state of microtubules and affects the development of axons. Studies have confirmed that nerve regeneration in brain trauma, epilepsy, and ischemic cerebrovascular disease is accompanied by up-regulation of MAP1B. Moreover, studies have shown that the number of myelinated fibers in the peri-nural nerve of MAP1B-deficient mice is significantly reduced, and the myelin sheath becomes thinner.
The study found that MAP1B is involved in the regulation of the growth direction of the axon growth cone. There are two forms of MAP1B and P-MAP1B in the body. It is found that these two forms regulate the growth of axons by mutual transformation, MAP1B stabilizes the polymerization of microtubules, and PMAP1B reverses. Moreover, P-MAP1B has been shown to be the most highly expressed in the axon near growth cone, thus making the microtubule system in axon regeneration a dynamic unstable state. Goold et al. believe that this unstable state was a necessary state for axon growth cone microtubules to extend and rotate during axon growth.
Schwann cells are the main glial components of the peripheral nerves. The myelin sheath of the peripheral nerve-derived fibers is formed by the morphological changes of Schwann cells and the laminarization of the plasma membrane to axons. According to the phenomenon that MAP1B and its mRNA are highly expressed in Schwann cells during sciatic nerve injury and regeneration, and MAP1B is also expressed in neonatal mouse Schwann cells cultured in vitro, studies have shown that MAP1B expressed in Schwann cells affects axonal regeneration and remyelination by supporting the morphological changes of Schwann cells during axonal regeneration and remyelination in the early stage after peripheral nerve injury.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.